Skip to main content Back to Top
Advertisement

1/26/2024

Idarubicin Injection

Products Affected - Description

    • Idamycin PFS, Pfizer, 1 mg/mL, 10 mL vial, 1 count, NDC 00013-2586-91
    • Idamycin PFS, Pfizer, 1 mg/mL, 20 mL vial, 1 count, NDC 00013-2596-91
    • Idamycin PFS, Pfizer, 1 mg/mL, 5 mL vial, 1 count, NDC 00013-2576-91
    • Idarubicin, Hikma, 1 mg/mL, 10 mL vial, 1 count, NDC 00143-9218-01
    • Idarubicin, Hikma, 1 mg/mL, 20 mL vial, 1 count, NDC 00143-9219-01
    • Idarubicin, Hikma, 1 mg/mL, 5 mL vial, 1 count, NDC 00143-9217-01

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Pfizer has Idamycin on shortage due to increased demand and manufacturing delays.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Hikma has idarubicin 1 mg/mL 5 mL, 10 mL, and 20 mL vials on back order and the company estimates a release date of late-February to early-March 2024.
    • Pfizer has Idamycin PFS 1 mg/mL 5 mL and 10 mL vials available in limited supply. The 20 mL vials are on back order and the company estimates a release date of August 2024.

Updated

Updated January 26, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 15, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.